{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"15.00","value":"8.50"}]}],"title":"IL-1β (Interleukin-1β)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"7320.00","value":"17.00"}]}],"title":"IL-6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45000","upperLimit":"641000","value":"292500"}]}],"title":"Factor VII"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"15000","value":"300"}]}],"title":"BDNF"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"140.00","value":"69.00"}]}],"title":"VEGF"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"126.00","upperLimit":"21200.00","value":"594.00"}]}],"title":"MCP-1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3000","upperLimit":"93000","value":"12000"}]}],"title":"MMP-3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"8930.00","value":"55.00"}]}],"title":"IL-8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"2240.00","value":"85.00"}]}],"title":"IL-5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"46.00","value":"0.00"}]}],"title":"ITAC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"}],"units":"Participants"}],"description":"Serum levels were determined for 38 circulating proteins. Selected values showing statistically significant difference compared with baseline are reported here.","dispersionType":"Full Range","groups":[{"description":"Participants received 1-2 cycles of induction (glasdegib and daunorubicin/cytarabine), followed by 2-4 cycles of consolidation (glasdegib and high dose cytarabine) and a maximum of 6 cycles of maintenance (glasdegib alone). Daunorubicin was given on Days 1-3 QD at a dose of 60 mg/m\\^2/day by IV together with cytarabine on Days 1-7 at a dose of 100 mg/m\\^2/day by continuous IV infusion for each cycle of induction. Cytarabine was given on Days 1, 3, and 5 at a dose of 1 g/m\\^2 administered as a 3-hour IV infusion every 12 hours (2 g/m\\^2/day) for each cycle of consolidation. Glasdegib tablets 100 mg QD was started on induction Cycle 1/Day -3 and administered continuously QD thereafter for the duration of the study. A cycle was defined as 28 days.","id":"OG000","title":"Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin"}],"paramType":"MEDIAN","populationDescription":"PD analysis set: all enrolled participants in the Phase 2 Fit portion who received at least 1 dose of glasdegib, and had at least 1 PD parameter from the corresponding assay sample with a baseline and an adequate post treatment assessment.","reportingStatus":"POSTED","timeFrame":"Induction Cycle 1/Day 10, 1 Hour Post dose","title":"Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 10","type":"SECONDARY","unitOfMeasure":"pg/mL"}